Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397: 671–81—In this Article, the funder list has been updated by removing one that was incorrectly listed; in figure 2, the number at risk at the day 20 timepoint has been corrected to 15 117; in figure 3B, the number of male participants labelled on the graph has been corrected to 46; and in the legend of figure 3, the following sentence has been added for clarity: “Four participants are not included in the subgroup analysis by age because of missing date of birth on the case report form for this analysis”. These corrections have been made to the online version as of Feb 18, 2021, and the printed version is correct.
Department of Error
Issue date 2021 20-26 February.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.